Skip to main content
SpringerLink
Log in

Les indications « standards » et « non standards » des traitements néo-adjuvants

  • Conference paper
Cancer du sein

  • 245 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Le Grand Robert de la langue française, 2e ed., Paris, 2001.

    Google Scholar 

  2. Fervers B, Bonichon F, Demard F et al. (1995) Méthodologie de développement des standards, options et recommandations diagnostiques et thérapeutiques en cancérologie. Bull Cancer 82: 761–7

    PubMed  CAS  Google Scholar 

  3. Jacquillat C, Baillet F, Auclerc G et al. (1984) Breast cancer: chemotherapy preceding locoregional treatment with extension of the indications for conservative treatment. Bull Cancer 71: 354–60

    PubMed  CAS  Google Scholar 

  4. Jacquillat C, Baillet F, Auclerc G et al. (1986) Neoadjuvant chemotherapy of breast cancer. Drugs Exp Clin Res 12: 147–52

    PubMed  CAS  Google Scholar 

  5. Haagensen CD, Stout AP (1943) Carcinoma of the breast. Criteria of inoperability. Am Surg 118: 859–66

    CAS  Google Scholar 

  6. Haagensen CD, Stout AP (1943) Carcinoma of the breast. Criteria of inoperability. Am Surg 118: 1032–40

    CAS  Google Scholar 

  7. Kaufmann M, von Minckwitz G, Smith R et al. (2003) International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol 21: 2600–8. Erratum in: J Clin Oncol 21: 4469

    Article  PubMed  Google Scholar 

  8. Schwartz GF, Hortobagyi GN (2004) Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26–28, 2003, Philadelphia, Pennsylvania. Cancer 100: 2512–32

    Article  PubMed  Google Scholar 

  9. Breast. In Green FL, Page DL, Fleming ID et al. (ed) (2002) AJCC Cancer staging handbook. 6th ed. New York, Springer: 255–81

    Google Scholar 

  10. Halsted WS (1894) The results of operations for the cure of cancer of the breast performed at the John Hopkins Hospital from June 1889-January. Johns Hopkins Hosp Bull 4: 1111

    Google Scholar 

  11. Early Breast Cancer Trialists’ Collaborative Group (1998) Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352: 930–42

    Article  Google Scholar 

  12. Grohn P, Heinonen E, Klefstrom P et al. (1984) Adjuvant postoperative radiotherapy, chemotherapy, and immunotherapy in stage III breast cancer. Cancer 54: 670–4

    PubMed  CAS  Google Scholar 

  13. De Lena M, Zucali R, Viganotti G et al. (1978) Combined chemotherapyradiotherapy approach in locally advanced (T3b–T4) breast cancer. Cancer Chemother Pharmacol 1: 53–9

    Article  PubMed  Google Scholar 

  14. Horobagyi GN, Singletary SE, Strom EA (2004) Locally advanced breast cancer. In: Harris JR, Lippman ME, Morrow M, Osborne K (eds) Diseases of the Breast. 3rd ed. Philadelphia: Lippincott Williams & Wilkins: 951–69

    Google Scholar 

  15. Lippman ME, Sorace RA, Bagley CS et al. (1986) Treatment of locally advanced breast cancer using primary induction chemotherapy with hormonal synchronization followed by radiation therapy with or without debul-king surgery. NCI Monogr 1: 153–9

    PubMed  Google Scholar 

  16. Fisher B, Brown A, Mamounas E et al. (1997) Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15: 2483–93

    PubMed  CAS  Google Scholar 

  17. Smith IC, Heys SD, Hutcheon AW et al. (2002) Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 20: 1456–66

    Article  PubMed  CAS  Google Scholar 

  18. Bear HD, Anderson S, Smith RE et al. (2004) A Randomized Trial Comparing Preoperative Doxorubicin/Cyclophosphamide (AC) to Preoperative AC Followed by Preoperative Docetaxel (T) and to Preoperative AC Followed by Postoperative T in Patients with Operable Carcinoma of the Breast: Results of NSABP B-27. Breast Cancer Res Treat 83(suppl. 1): abs 26

    Google Scholar 

  19. Pouillart P, Fumoleau P, Romieu G et al. (1999) Final Results of a Phase II Randomized, Parallel Study of Doxorubicin/Cyclophosphamide (AC) and Doxorubicin/Taxol (paclitaxel) (AT) as Neoadjuvant Treatment of Local-Regional Breast Cancer. Proc Annu Meet Am Soc Clin Oncol 18: abs 275

    Google Scholar 

  20. Untch M, Konecny G, Ditsch N et al. (2002) Dose-dense sequential epirubicin-paclitaxel as preoperative treatment of breast cancer: results of a randomised AGO study. Proc Annu Meet Am Soc Clin Oncol 21: abs 133

    Google Scholar 

  21. Jackisch C, von Minckwitz G, Eidtmann H et al. (2002) Dose-dense biweekly doxorubicin/docetaxel versus sequential neoadjuvant chemotherapy with doxorubicin/cyclophosphamide/docetaxel in operable breast cancer: second interim analysis. Clin Breast Cancer 3: 276–80

    Article  PubMed  CAS  Google Scholar 

  22. Green MC, Buzdar AU, Smith T et al. (2002) Weekly paclitaxel (P) followed by FAC as primary systemic chemotherapy of operable breast cancer improves pathologic complete remission rates when compared to every 3-weekly P therapy followed by FAC-final results of a prospective phase III randomized trial. Proc Annu Meet Am Soc Clin Oncol 21: abs 135

    Google Scholar 

  23. Mauriac L, Debled M, Durand M et al. (2002) Neoadjuvant tamoxifen for hormone-sensitive non-metastatic breast carcinomas in early postmenopausal women. Ann Oncol 13: 293–8

    Article  PubMed  CAS  Google Scholar 

  24. Bell CA (1814) A system of operative surgery. Surgery 11: 136

    Google Scholar 

  25. Leartmonth GE (1916) Acute mammary carcinoma (Volmann’s mastitis carcinomatosa). Can Med Assoc J 6: 511

    Google Scholar 

  26. De Lena M, Varini M, Zucali R et al. (1981) Multimodal treatment for locally advanced breast cancer. Result of chemotherapy-radiotherapy versus chemotherapy-surgery. Cancer Clin Trials 4: 229–36

    PubMed  Google Scholar 

  27. Rouesse J, Friedman S, Sarrazin D et al. (1986) Primary chemotherapy in the treatment of inflammatory breast carcinoma: a study of 230 cases from the Institut Gustave-Roussy. J Clin Oncol 4: 1765–71

    PubMed  CAS  Google Scholar 

  28. Chevallier B, Roche H, Olivier JP et al. (1993) Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol 16: 223–8

    PubMed  CAS  Google Scholar 

  29. Palangie T, Mosseri V, Mihura J et al. (1994) Prognostic factors in inflammatory breast cancer and therapeutic implications. Eur J Cancer 30A: 921–7

    Article  PubMed  CAS  Google Scholar 

  30. Viens P, Palangie T, Janvier M et al. (1999) First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial). Br J Cancer 81: 449–56

    Article  PubMed  CAS  Google Scholar 

  31. Merajver SD, Sabel MS (2004) Inflammatory breast cancer. In: Harris JR, Lippman ME, Morrow M, Osborne K eds. Diseases of the Breast. 3rd ed. Philadelphia: Lippincott Williams & Wilkins 971–82

    Google Scholar 

  32. Charafe-Jauffret E, Tarpin C, Bardou VJ et al. (2004) Immunophenotypic analysis of inflammatory breast cancers: identification of an “inflammatory signature”. J Pathol 202: 265–73

    Article  PubMed  Google Scholar 

  33. Parton M, Dowsett M, Ashley S et al. (2004) High incidence of HER-2 positivity in inflammatory breast cancer. Breast 13: 97–103

    Article  PubMed  CAS  Google Scholar 

  34. Wolmark N, Wang J, Mamounas E et al. (2001) Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 30: 96–102

    PubMed  Google Scholar 

  35. Fisher B, Jeong JH, Bryant J et al. (2004) Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet 364: 858–68

    Article  PubMed  CAS  Google Scholar 

  36. National Institutes of Health Consensus Development Panel (2001) National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer, November 1–3 2000. J Natl Cancer Inst Monogr 30:5–15

    Google Scholar 

  37. Goldhirsch A, Wood WC, Gelber RD et al. (2003) Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 21: 3357–65

    Article  PubMed  Google Scholar 

  38. Veronesi U, Cascinelli N, Mariani L et al. (2002) Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 17 347: 1227–32

    Article  PubMed  Google Scholar 

  39. Fisher B, Anderson S, Bryant J et al. (2002) Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347:1233–41

    Article  PubMed  Google Scholar 

  40. Morrow M, Harris JR (2004) Local management of invasive cancer: breast. In: Harris JR, Lippman ME, Morrow M, Osborne K (eds) Diseases of the Breast. 3rd ed. Philadelphia: Lippincott Williams & Wilkins: 719–44

    Google Scholar 

  41. Clough KB, Lewis JS, Couturaud B et al. (2003) Oncoplastic techniques allow extensive resections for breast-conserving therapy of breast carcinomas. Ann Surg 237: 26–34

    Article  PubMed  Google Scholar 

  42. Mauriac L, MacGrogan G, Avril A et al. (1999) Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS). Ann Oncol 10: 47–52

    Article  PubMed  CAS  Google Scholar 

  43. Scholl SM, Fourquet A, Asselain B et al. (1994) Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. Eur J Cancer 30A: 645–52

    Article  PubMed  CAS  Google Scholar 

  44. Powles TJ, Hickish TF, Makris A et al. (1995) Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol 13: 547–52

    PubMed  CAS  Google Scholar 

  45. van der Hage JA, van de Velde CJ, Julien JP et al. (2001) Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 19: 4224–37

    PubMed  Google Scholar 

  46. Gazet JC, Markopoulos C, Ford HT et al. (1988) Prospective randomised trial of tamoxifen versus surgery in elderly patients with breast cancer. Lancet 1:679–81

    Article  PubMed  CAS  Google Scholar 

  47. Bates T, Riley DL, Houghton J et al. (1999) Breast cancer in elderly women: a Cancer Research Campaign trial comparing treatment with tamoxifen and optimal surgery with tamoxifen alone. The Elderly Breast Cancer Working Party. Br J Surg 78: 591–4

    Google Scholar 

  48. Mustacchi G, Ceccherini R, Milani S et al. (2003) Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: long-term results of the phase III randomized controlled multicenter GRETA trial. Ann Oncol 14: 414–20

    Article  PubMed  CAS  Google Scholar 

  49. Willsher PC, Robertson JF, Armitage NC et al. (1996) Locally advanced breast cancer: long-term results of a randomized trial comparing primary treatment with tamoxifen or radiotherapy in post-menopausal women. Eur J Surg Oncol 22: 34–7

    Article  PubMed  CAS  Google Scholar 

  50. Robertson JF, Todd JH, Ellis IO et al. (1988) Comparison of mastectomy with tamoxifen for treating elderly patients with operable breast cancer. BMJ 297:511–4

    Article  PubMed  CAS  Google Scholar 

  51. Dixon JM (2002) Neoadjuvant therapy surgical perspectives. In: Miller WR, Ingle JN eds. Endocrine therapy in breast cancer, New York: Marcel Dekker, 197

    Google Scholar 

  52. Ellis MJ, Coop A, Singh B et al. (2001) Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1-and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 19: 3808–16

    PubMed  CAS  Google Scholar 

  53. Smith I, Dowsett M on behalf of the IMPACT Trialists (2003) Comparison of anastrozole vs tamoxifen alone and in combination as neoadjuvant treatment of estrogen receptor-positive (ER+) operable breast cancer in postmenopausal women: the IMPACT trial. Breast Cancer Res Treat 82(Supp 1): abs 1

    Google Scholar 

  54. Faneyte IF, Schrama JG, Peterse JL et al. (2003) Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Br J Cancer 88: 406–12

    Article  PubMed  CAS  Google Scholar 

  55. Penault-Llorca F, Vincent-Salomon A (2004) Chimiothérapie néo-adjuvante: place du pathologiste. Evaluation de la réponse, facteurs pronostiques et prédictifs. Oncologie 6: 169–74

    Google Scholar 

  56. Massimo Cristofanilli, Ana Gonzalez-Angulo, Nour Sneige et al. (2005) Invasive Lobular Carcinoma Classic Type: Response to Primary Chemotherapy and Survival Outcomes. J Clin Oncol 23: 41–8

    Google Scholar 

  57. Ollivier L, Balu-Maestro C, Chapellier C, Leclère J (2004) Evaluation par l’imagerie des traitements néoadjuvants des cancers du sein. Oncologie 6: 164–8

    Article  Google Scholar 

  58. Holland R, Veling SH, Mravunac M, Hendriks JH (1985) Histologic multifocality of Tis, T1-2 breast carcinomas. Implications for clinical trials of breastconserving surgery. Cancer 56: 979–90

    PubMed  CAS  Google Scholar 

  59. Pouillart P (2004) Chimiothérapie néo-adjuvante: justificatif historique et expérimental. Oncologie 6: 147–9

    Article  Google Scholar 

  60. Clahsen PC, van de Velde CJ, Julien JP (1996) Improved local control and disease-free survival after perioperative chemotherapy for early-stage breast cancer. A European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group Study. J Clin Oncol 14: 745–53

    PubMed  CAS  Google Scholar 

  61. Tagliabue E, Agresti R, Carcangiu ML et al. (2003) Role of HER2 in woundinduced breast carcinoma proliferation. Lancet 362: 527–33

    Article  PubMed  CAS  Google Scholar 

  62. Hortobagyi GN (2004) Opportunities and challenges in the development of targeted therapies. Semin Oncol 31(Suppl 3): 21–7

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Oncologie Médicale, CancerEst, Hôpital Tenon, Assistance publique-Hôpitaux de Paris, Université Paris VI, 4, rue de la Chine, 75020, Paris

    J. Gligorov

  2. Amicale Franco Macédonienne Oncologique, Skopje, Macédoine

    J. Gligorov, P. Debourdeau & O. Arsovski

  3. Médecine interne oncologie, HIA Desgenettes Lyon, France

    P. Debourdeau

  4. Oncologie Radiothérapie, CHU Skopje, Macédoine

    O. Arsovski

  5. Oncologie médicale, CancerEst, Hôpital Tenon, 4, rue de la Chine, 75020, Paris

    V. Todorovic

  6. Oncologie radiothérapie, CHU Podgorica, Monténégro

    V. Todorovic

  7. Gynécologie Obstétrique, Université Paris VI, Cancerest, Hôpital Tenon, 4, rue de la Chine, 75020, Paris

    S. Uzan

  8. Oncologie médicale, Université Paris VI, Cancerest, Hôpital Tenon, 4, rue de la Chine, 75020, Paris

    J. -P. Lotz

Authors
  1. J. Gligorov
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Debourdeau
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. O. Arsovski
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. V. Todorovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S. Uzan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J. -P. Lotz
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer-Verlag France, Paris

About this paper

Cite this paper

Gligorov, J., Debourdeau, P., Arsovski, O., Todorovic, V., Uzan, S., Lotz, J.P. (2006). Les indications « standards » et « non standards » des traitements néo-adjuvants. In: Cancer du sein. Springer, Paris. https://doi.org/10.1007/2-287-31109-2_15

Download citation

  • DOI: https://doi.org/10.1007/2-287-31109-2_15

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-25174-0

  • Online ISBN: 978-2-287-31109-3

Publish with us

Policies and ethics

Search

Navigation